In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the bone, liver, lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of novel chemotherapeutics involving targeting agents and unique dosage forms. We provide a historical overview of BCBM chemotherapy, review the mechanisms of new agents such as poly-ADP ribose polymerase inhibitors, cyclin-dependent kinase 4/6 inhibitors, phosphatidyl inositol 3-kinaseinhibitors, estrogen pathway antagonists for hormone-receptor positive BCBM; tyrosine kinase inhibitors, antibodies, and conjugates for HER2 + BCBM; repurposed cytotoxic chemotherapy for triple negative BCBM; and the utilization of these new agents and formulations in ongoing clinical trials. The mechanisms of novel dosage formulations such as nanoparticles, liposomes, pegylation, the concepts of enhanced permeation and retention, and drugs utilizing these concepts involved in clinical trials are also discussed. These new treatments provide a promising outlook in the treatment of BCBM.
metastases necessitates the development of novel treatment strategies, which will be highlighted in this review.
Physiology/pathology

Blood-brain barrier
Blood vessels, which deliver blood from the heart to different organs, have different properties to meet the requirements of the particular organ or tissue they vascularize [14] . Neurons of the brain communicate by chemical and electrical signals, which give rise to their function. For these signals to be reliable and reproducible, the ionic concentration of the tissue has to be constant to maintain homeostasis [15] . The microvasculature of the brain plays an important role in regulating the entry of any solute into the brain parenchyma and undisrupted function is required to maintain homoeostasis for proper neuronal function [15] . This unique property of brain microvasculature is described as the blood-brain barrier ( Fig. 2A) . Continuous, non-fenestrated capillaries form the BBB, in which endothelial cells are attached together by tight junction protein complexes including claudins, occludins, and intercellular adhesion molecules. These junctional components restrict the paracellular diffusion of solutes [16, 17] . The brain endothelial cells also restrict vesicle mediated transcellular movement more so than endothelial cells in the periphery [18] . Surrounded by pericytes on the abluminal side, these cells have contractile proteins that regulate the diameter of the capillary [19] . Astrocytic foot processes also cover microvasculature, providing a link between neurons and blood vessels. Through this cellular link, astrocytes mediate blood flow in accordance with neuronal activity [20, 21] . Astrocytes play an important role in the formation of the BBB, and factors secreted by astrocytes play an important role in BBB function [22] . In addition to the physical barrier properties of brain capillaries, a great number of chemical barriers also exist in the BBB. Efflux transporters including pglycoprotein, the breast cancer resistance protein, and the family of multi-drug resistance proteins are expressed on brain endothelium, which limit lipophilic solutes form entering the brain [23, 24] . Enzymes secreted by the BBB (e.g., phosphatases) inactivate larger molecules including peptides and neuropeptides, preventing their passing through the BBB [25, 26] .
Functions of BBB
The BBB provides a stable and partially sequestered environment for neuronal activity by means of ion regulation. Ion concentrations are kept relatively constant despite the changes in plasma ion concentration due to acute or chronic changes in conditions [27] [28] [29] . The BBB also separates central neurotransmitters from peripheral neurotransmitters. For example, the peripheral neuroexcitatory amino acid glutamate is present at high concentrations in peripheral blood and would cause permanent neurotoxic damage if allowed to enter the brain [30] . Macromolecules like albumin, pro-thrombin, and plasminogen may initiate apoptosis and are detrimental to central nervous system, but are restricted by the BBB [31, 32] . Aside from restricting potentially toxic substances, the BBB also plays an important role in regulating nutrition to the brain. Specific transport systems are in place for essential water-soluble nutrients [30] . Many pathways regulate angiogenesis and vasculogenesis, including vascular endothelial growth factor (VEGF) and its receptors (VEGFR). Notch signaling also plays an important role in regulating endothelial cell functions [33, 34] .
While the BBB helps maintain homeostasis to support proper brain function, it also restricts delivery of many drugs, including chemotherapy, to the central nervous system (CNS) [35] . Agents such as paclitaxel and doxorubicin are significantly subjected to efflux Cancer cells stimulate new vasculature to form, which is immature and have fenestrated openings, allowing substances normally restricted to more easily access brain parenchyma. BCRP: breast cancer resistance protein; MRP-1: multidrug resistance-associated protein-1; PGP: P-glycoprotein.
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Blood-tumor barrier
Once metastatic lesions begin to develop in the brain, BBB integrity is lost and the resulting tumor microvasculature is often referred to as the blood-tumor-barrier (BTB) (Fig. 2B) [13] . As metastases grow, they promote the growth of new blood vessels via angiogenesis. These new blood vessels lack tight junctions and proper astrocytic contact. As a result the BTB has increased permeability and reduced blood flow [39] [40] [41] . In addition, the angiogenic vessels have fenestrations, which increase permeability through paracellular pathways [42, 43] , allowing normally regulated substances to freely enter the tumor and its microenvironment.
However, BTB permeability is not homogenous from tumor to tumor or even within the metastatic lesion [44] . Significant heterogeneity exists within and between tumors based on findings from preclinical breast cancer brain metastases models [13, 45] . Brain metastases become hypoxic as they grow beyond their blood supply. To meet their oxygen and nutrition requirements, tumor cells secrete vascular endothelial growth factor (VEGF) to initiate the process of new blood vessel formation [46] . VEGF secretion is associated with increased turnover of endothelial cells leading to increased permeability [46] . Angiogenesis is a dynamic process, to which the heterogeneity of BTB permeability between tumors can be attributed [47, 48] .
A multitude of factors exist that make treatment of BCBM difficult. These factors can be anatomical or tumor-related. The region around the tumor, called the tumor microenvironment, has physiological conditions that vary from the normal tissue physiology. One such difference is hypoxia. Hypoxia induces resistance to drug and radiation therapy [49] . A few conventional chemotherapy drugs such as bleomycin, etoposide, and cyclophosphamide, require oxygen to exert their cytotoxic effects [50] . Thus, under hypoxic conditions, these drugs fail to have an optimal cytotoxic effect leading to tumor resistance.
Effects of the BBB and BTB on drug therapy
Although lipophilic drugs have higher tendency to cross the BBB, many drugs achieving this feat are subject to efflux by the efflux pumps of the BBB. The primary efflux transporters belong to the ATP-binding cassette transporter family. Found on the luminal side of the BBB, these include the P-glycoprotein (P-gp), breast cancer resistance protein, and the multi-drug resistance protein [51] . Amongst them, the P-gp, present on both luminal and abluminal side, serves to remove a wide variety of substrates including chemotherapeutic drugs such as paclitaxel. The breast cancer resistance protein efflux transporter is also an important contributing factor in chemotherapy resistance. The BBB is dynamic in nature, and changes are seen in its integrity in different disease states, including metastatic cancer [52] . As stated previously the BTB has a higher permeability to chemotherapy as compared to the intact BBB; however therapeutic concentrations of drug are still unable to get across to the desired site. To add to the challenge, the BTB is highly variable in nature, which leads to variable drug concentrations reaching the target [53] . Chemotherapeutic drugs paclitaxel and doxorubicin were found to penetrate the BTB more easily compared to BBB in a brain metastatic mouse model of breast cancer; however, the drug concentrations in tumor were sub-therapeutic and non-uniform [13, 54] . Circumventing the BBB, BTB, and the efflux processes remain the ultimate challenge for the effective therapy of brain metastases.
Subsets of breast cancer brain metastases
Hormone receptor-positive
Hormone receptor-positive (HR + ) breast cancer is a subtype of breast cancer that expresses estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These types of tumors respond differently to treatment and confer a variety of prognoses [55] . Although PR are typically regulated by ER, they can act independently at times, creating the three types of HR + BC: ER positive/PR positive, ER positive/PR negative, and ER negative/ PR positive [55] [56] [57] [56, 57] . The estrogen and progesterone signaling pathways are very similar representations of the typical steroid mechanism [55] . Although there are different types of ER and PR in cells, the main targets of medication are the nuclear transcription factors (i.e. ERα) responsible for cellular growth and proliferation [55, 57] . The endogenous hormones freely diffuse through the cell membrane to their respective protein receptors, which dimerize upon binding their hormone and translocate into the nucleus to bind DNA and activate transcription [55] . The HR + BC subtypes tend to be more treatable than other BC subtypes due to the significant effectiveness of endocrine therapy on ER + BC [55] .
Hormone positive therapy
There are no chemotherapeutic agents or regimens specifically approved for hormone receptor-positive BCBM, however many are being investigated through clinical trials [58] . Multiple studies have demonstrated that the luminal subtypes of breast cancer (luminal A and luminal B) are associated with decreased likelihood of brain metastasis [59] [60] [61] . However, some chemotherapeutic research is being done for the rare cases when hormone receptor positive breast cancer does metastasize to the brain. In 1991, Lien et al. determined tamoxifen and its metabolites achieved 46 times higher concentrations in brain tissue compared to serum levels [62] . Then in 2006, a phase 1 trial was conducted with 24 BCBM patients receiving a combination of capecitabine and temozolomide [63] . The study reported one complete response and three partial responses warranting the need for further research regarding this therapy [63] . Three years later a retrospective study examined five BCBM patients who were treated concurrently with capecitabine and WBRT [64] . Of the five, one achieved a complete response, two achieved partial responses, one had stable disease, and one patient was deceased [64] . Three years after the previous study, Addeo et al. conducted a trial with the combination of vinorelbine, temozolomide, and WBRT in 36 patients [65] . This study reported three complete and 16 partial responses, with a PFS and OS of eight and 11 months, respectively [65] . After another three-year period, eribulin was compared to capecitabine in the treatment of HR + MBC with metastatic breast cancer of the brain (MBCB). All three selected patients from the study who received eribulin displayed brain lesion shrinkage during the study and fewer total patients developed new BCBM with eribulin than with capecitabine [66] . This study notes that eribulin does not cross a healthy BBB but capecitabine may [66] . That same year, Niravath et al. concluded that concomitant treatment of capecitabine and WBRT followed by capecitabine and sunitinib did not extend PFS and was associated with significant toxicity [67] . Furthermore, in 2015, a prospective study comparing BCBM versus serum concentrations for capecitabine and lapatinib concluded that both drugs penetrate BCBM to a significant albeit variable degree [68] . The American Society of Clinical Oncology recommends endocrine therapy as the initial
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In a Phase 3 trial, 576 patients received this combination with median PFS of 6.9 months vs. 5 months in placebo group. The most common grade 3-4 AE were increased hepatic enzymes (∼25%), hyperglycemia (15%), and rash (8%) [196] .
The results show that PI3K inhibition combined with endocrine therapy is effective but no further studies are being pursued with this combination due to the toxicity. Capecitabine appears to cross the BBB and have activity in BCBM.
Sunitinib
In a Phase 2 trial, 12 patients with BCBM first received capecitabine with radiation therapy followed by capecitabine with sunitinib. The trial was closed due to slow accrual but median PFS was 4.7 months and OS was 10 months [67] .
There was no extension of PFS and this combination was considered significantly toxic.
In a prospective study, 8 BCBM patients received capecitabine 2-3 h before surgical resection of BCBM tumor to assess drug levels in BCBM tissue. There were measurable amounts of capecitabine and its metabolites in BCBM tissue but BCBM to serum ratio was higher for 5-fluorouracil than capecitabine [68] .
Capecitabine was able to penetrate the BBB, though to a variable degree.
WBRT
In this retrospective study, 5 BCBM patients received capecitabine with WBRT. One patient had a complete response, two had partial responses and one had stable disease [64] .
Z-Endoxifen
In a Phase 1 trial, 38 HR + endocrine-refractory MBCB patients received Z-Endoxifen. Overall clinical benefit rate was 26.3% [198] . Eribulin In a Phase 3 trial, 544 patients with MBCB received eribulin. Overall survival was 15.9 months and PFS was 4.1 months and 13 patients developed new BCBM [66] .
Eribulin does not cross a healthy BBB but may be able to do so in combination with radiation therapy.
Sixty-six patients with pre-treated MBCB received eribulin monotherapy. Median PFS was 5 months and OS was 8 months, 15 patients had PR, and 36 had stable disease [199] .
Eribulin monotherapy was deemed safe and effective as a result of this study.
Estradiol Exemestane In a pilot study, 13 patients received estradiol and 6 (46%) had no progression at 3 months and were then switched to exemestane. Of the 6 on exemestane, 5 had disease progression and 1 had stable disease. Median PFS was 4.8 months [200] . Lapatinib
In a prospective study, 4 BCBM patients received 2-5 doses of lapatinib daily with the last being 2-3 h before surgical resection of BCBM tumor to assess drug levels in BCBM tissue. The median BCBCM concentrations ranged from 1.0-6.5 μM [68] .
Lapatinib was able to penetrate the BBB, though to a variable degree.
Paclitaxel Pictilisib
In the Phase 2 PEGGY study, paclitaxel was combined with pictilisib or a placebo for 183 eligible patients. The PFS for the pictilisib group was 8.2 months versus the placebo group which was 7.8 months [201] . Pilaralisib Letrozole In a Phase 1 & 2 dose escalation study, 21 patients were enrolled in Phase 1 to determine the MTD and 51 patients were enrolled in Phase 2 which determined efficacy using the MTD. One patient had a PR and the rate of PFS at 6 months was 17%. The most common grade ≥3 AE were increased hepatic enzymes (5%) and rash (5%) [202] . Table 3 . An illustration of overall mechanisms is provided in Fig. 3 .
CDK4/6 inhibitors
Three cyclin-dependent kinase CDK-4 and -6 (CDK 4/6) inhibitors are being evaluated for their effects in treating hormone-positive BCBM: abemaciclib, palbociclib, and ribociclib. Abemaciclib has proved to be a safe and effective treatment for HR + /HER2 − metastatic breast cancer in three separate MONARCH trials, the second of which earned the drug approval from the FDA [70] [71] [72] [73] . However, women with CNS metastases were excluded from all three trials, raising the question of abemaciclib's efficacy for the treatment of BCBM. Subsequently, there are a few ongoing trials of abemaciclib that include patients with HR + BCBM. The first is a Phase 2 study specifically looking at abemaciclib's safety and effectiveness in participants with BM from non-small cell lung cancer, melanoma, and HR + BC (NCT02308020 In the BELLE-4 study, buparlisib was paired with paclitaxel in the treatment of asymptomatic HER2 − metastatic BCBM. Though overall results were posted for 338 patients, no specific results were posted for BM patients (NCT01572727). This trial was meant to be a Phase 2 study followed by a Phase 3, but was ended after the second phase due to predefined futility criteria as there was no improvement in progression free survival [74] . Subsequently, buparlisib was paired with fulvestrant in two separate Phase 3 studies, BELLE-2 and BELLE-3, evaluating its effectiveness in treating asymptomatic HR + /HER2 − BCBM after disease progression on an aromatase inhibitor (BELLE-2) or an mTOR inhibitor (BELLE-3) (NCT01610284, NCT01633060). In a second experimental group of the Phase 1 B-YOND study, the PI3K inhibitor buparlisib will be combined with tamoxifen and goserelin (NCT02058381). Although no results have been posted, buparlisib completed a Phase 1 study in combination with letrozole in which BCBM patients were included (NCT01248494). In the Phase 2 STAR Cape study, buparlisib will be combined with capecitabine to treat any type of BCBM, though the HER2 + subset is also receiving trastuzumab (NCT02000882).
In a second experimental group from a previously mentioned completed phase 1 study, dactolisib will be combined with letrozole for BCBM participants (NCT01248494). [65] . Voxtalisib Letrozole In a Phase 1 & 2 dose escalation study, 21 patients were enrolled in Phase 1 to determine the MTD and 51 patients were enrolled in Phase 2 which determined efficacy using the MTD. No patients responded and the rate of PFS at 6 months was 8%. The most common grade ≥3 AE were increased hepatic enzymes (11%) and rash (9%) [202] .
The safety was acceptable but the efficacy was limited.
Compared to standard chemotherapy, targeted agents have a better response rate and newer agents have fewer side effects. AE: adverse events; MBCB: metastatic breast cancer of the brain, MTD: maximum therapeutic dose; ORR: overall response rate; OS: overall survival; PFS: progression-free survival. Table 2 In-progress and upcoming clinical trials involving hormone-positive BCBM. In a Phase 2 trial of 4 BCBM patients, 1 achieved a PR [204] . Though it has poor CSF penetration, cisplatin can penetrate the blood-tumor barrier.
In 56 patients treated with the combination, 7 achieved CR, 14 PR, 12 did not change, 16 progressed, and 8 were not assessed, for an overall 38% response rate [90] . Doxorubicin Cisplatin, doxorubicin, methotrexate and 5-fluorouracil caused major toxicity with no improvement in 4 BCBM patients [205] . Cyclophosphamide 6 patients achieved a PR in a Phase 2 trial of 15 patients with BCBM [92] . Gemcitabine
In a trial of 15 BCBM, 4 of 6 were triple negative and achieved a response [94] . Vinorelbine
In combination with a 30 Gy radiation schedule, a Phase 2 trial of 25 patients with cisplatin and vinorelbine resulted in 3 CR and 16 PR (76%) [93] .
Cyclophosphamide
Cisplatin See cisplatin.
Methotrexate, 5-fluorouracil, vincristine, doxorubicin
Cyclophosphamide, methotrexate, and 5-fluorouracil were given to 20 patients with 13 attaining a positive response [206] . In 56 patients treated with cyclophosphamide, methotrexate, 5-fluorouracil and doxorobucin, PFS lengthened but no significant intracranial metastases-free interval [207] . In 27 of 52 patients (52%) with BCBM, response was achieved with cyclophosphamide, 5-fluorouracil and prednisone, 19 of 35 patients (54%) achieved response with cyclophosphamide, 5-fluorouracil, prednisone, methotrexate and vincristine, and 1 of 6 (17%) achieved response with cyclophosphamide and doxorubicin [208] .
Doxorubicin Cisplatin See cisplatin.
Cyclophosphamide
See cyclophosphamide.
Topotecan, ifosfamide
5 BCBM patients treated with the triple combination, with progressive disease occurring 2 of 5 [209] . Teniposide, lomustine 8 patients were treated with this triple therapy, 5 showed improvement and symptom regression [210] .
Eribulin
In one patient, eribulin was initiated as fifth-line therapy. Response was seen after one month, but ultimately the patient succumbed [211] . In three heavily treated patients, eribulin was found to be beneficial [66] . With concurrent whole-brain radiation therapy, eribulin regressed two brain metastases [212] . 
5-fluorouracil
mTOR inhibitors
In two ongoing Phase 1 trials, everolimus is being explored in combination with letrozole and trastuzumab for HR + BCBM patients (NCT02152943, NCT02269670). In a Phase 2 study, everolimus was combined with an anti-estrogen drug using similar criteria as Phase 1 trials (NCT02291913). In the Phase 2 LEO trial, everolimus is combined with letrozole and leuprorelin following disease progression with tamoxifen with or without a GnRH agonist (NCT02344550). In the Phase 3 MAIN-A study, everolimus is combined with an aromatase inhibitor as part of a maintenance regimen for HR + /HER2 − BCBM following treatment with one line of chemotherapy (NCT02511639).
Estrogen pathway antagonists
In addition to the trials listed above, anastrozole is being combined with the CDK4/6 inhibitor palbociclib in a Phase 2 study (02942355). In the phase 3 FEVEX study, fulvestrant is followed by exemestane and everolimus in the setting of symptomatic BM (NCT02404051). In a phase 2 study, fulvestrant is being investigated with and without ganetespib (NCT01560416). Fulvestrant is being utilized with/without lapatinib in a Phase 3 study (NCT00390455). Alisertib (MLN8237), an Aurora A kinase inhibitor, proved to be ineffective in Phase 3 trials, but is now being combined with fulvestrant in a Phase 1 study (NCT02219789).
GDC-0810, a selective estrogen receptor degrader, is being tested in a Phase 1 and 2 study as monotherapy and in combination with palbociclib and/or a luteinizing hormone-releasing hormone agonist (NCT01823835). Elacestrant (RAD-1901), another selective estrogen receptor modulator, is in two Phase 1 studies for HR + BCBM patients 
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VEGF inhibitors
Cabozantinib, an inhibitor of c-Met and VEGFR2, is being trialed with and without trastuzumab in BCBM patients in a Phase 2 study that spans across HR + , HER2
+ , and triple-negative subtypes (NCT02260531). In another Phase 2 study, cabozantinib is combined with fulvestrant (NCT01441947). Lenvatinib, a tyrosine kinase inhibitor against VEGFR receptors, is being combined with letrozole in a Phase 1 and 2 study on asymptomatic HR + BCBM (NCT02562118).
3.3.7. Insulin-like growth factor receptor antibodies Xentuzumab (BI836845), an insulin-like growth factor receptor 1 antibody, and abemaciclib are being investigated with and without hormonal therapy (NCT03099174). The insulin-like growth factor-1 inhibitor BMS-754807 completed a Phase 2 study where it was tried with and without letrozole, but results have not been published (NCT01225172).
Triple negative
The absence of ER, PR, and HER2 receptors (ER − , PR
− ) in breast cancer cells is termed triple negative or the basal subtype. Triple negative breast cancer (TNBC) is aggressive and tends to affect younger women. Due to the lack of targeting options, TNBC often has a high rate of recurrence and a worse prognosis than other breast cancer subtypes [75] [76] [77] . TNBC make up approximately 30% of all BCBM, with approximately 40% of metastatic TNBC eventually developing brain metastases [78] . As such, therapy is primarily with systemic cytotoxic therapy. TNBC typically have an initial response to chemotherapy that often relapses to cause large numbers of chemoresistant metastases [79] .
Systemic chemotherapy
Chemotherapy clinical trials have typically excluded patients with brain metastases for a variety of reasons, including limited penetration of agents through the BBB and BTB, the lack of a convenient modality for tumor burden monitoring, and poor overall survival prognoses leading to negative outcomes for patients [80] . Some of the earliest published work in chemotherapy for brain tumors began in the 1950s and 1960s, focusing on use of systemic agents such as methotrexate, thioTEPA, nitrosoureas, and vinca alkaloids [81] [82] [83] [84] . Kofman et al. noted the use of prednisolone to reduce neurological symptoms in 1957 [85] . Though the chemotherapy field has advanced, a regimen specific for the treatment of BCBM has yet to be approved and ratified by the Food and Drug Administration (FDA) or national and international cancer organizations. Systemic cytotoxic therapy including taxanes (docetaxel, paclitaxel), anthracyclines (doxorubicin), platinum compounds (cisplatin), and alkylating agents (cyclophosphamide) in combination with other agents have shown some efficacy in small studies [86] [87] [88] [89] . The rise of novel dosage forms, immunotherapy, and small molecule inhibitors has pushed the envelope of treatment expectations and produced trials focusing specifically on BCBM.
Traditional chemotherapy
Various combinations of cisplatin, etoposide, doxorubicin, 5-fluorouracil, methotrexate, vincristine, teniposide, lomustine, irinotecan, gemcitabine, paclitaxel, and temozolomide have been trialed in BCBM patients. Of these combinations, cisplatin-etoposide [90] alone or pretreated with bevacizumab [91] , cisplatin-cyclophosphamide [92] , cisplatin-vinorelbine [93] , and cisplatin-gemcitabine [94] showed significant efficacy. Full descriptions of nonspecific chemotherapeutic regimens and descriptions are provided in Table 3 .
Based on clinical trials, cisplatin has become the backbone for treating both primary BC as well as BM. Cisplatin, bevacizumab, and etoposide were combined for a Phase 2 trial of 8 BCBM patients in Taiwan, showing effect in 5 [95] . Cisplatin is being combined with veliparib, a PARP-inhibitor, for treating triple-negative and BRCA-mutated BC and associated BM (NCT02595905). As a single agent, temozolomide has been explored to treat brain metastases of breast cancer, lung cancer, and melanoma (NCT00831545) Eribulin, though not a targeted agent, is noted for its potential response in both triple-negative and HER2
+ patients, and is being studied in a Phase 2 trial in the treatment of HER2 + BCBM (NCT02581839). Fig. 3 illustrates the mechanism of traditional chemotherapy.
HER2
+ HER2 overexpression is found in 20-25% of all breast cancer cases [96] . As a plasma membrane-bound receptor tyrosine kinase (RTK), HER2 upregulation increases signaling from the extracellular environment for promotion of cellular survival and proliferation through a variety of downstream effectors [97] . Significantly, the HER2 + and TNBC subtypes have been shown to metastasize to the brain at higher rates than other BC subtypes [98] [99] [100] [101] . The enhanced extracranial systemic management of HER2 + metastatic BC with HER2-therapies trastuzumab and pertuzumab in addition to chemotherapy has contributed to the increased incidence of BM in this group [97] . One of the major pathways involved in the HER2-targeted therapy resistance essential to survival of HER2 + BC cells that colonize the brain is that of PI3K. The PI3K pathway that transmits signals of cell cycle progression and survival to the central circuitry of the cell is over-activated via the mechanisms of PTEN loss and acquisition of activating mutations in the PI3K gene in trastuzumab-resistant BC [102] [103] [104] .
HER2 + therapy
Treatment of HER2 + metastatic breast cancer with pHER2-targeted monoclonal antibody rhuMAb was first shown to have efficacy in patients who had received extensive prior chemotherapy in a Phase 2 study conducted by Baselga et al. in 1996 [105] . Two years later a phase 2 study showed that the combination of rhuMAb and cisplatin produced higher clinical response rates in metastatic BC patients than either as a monotherapy [106] . Just a few years later in 2001, Slamon et al. demonstrated that HER2-targeted monoclonal antibody trastuzumab in addition to either an anthracycline and cyclophosphamide combination, paclitaxel, or chemotherapy compared to each alone produced significantly longer progression-free survival (PFS) [107] . Recently in 2015, Swain et al. reported the most recent analysis of the CLEOPATRA trial [77] in which pertuzumab, a monoclonal antibody targeting a different epitope on the extracellular portion of HER2 than trastuzumab, was added to trastuzumab and docetaxel for the treatment of metastatic BC [108] . The addition of pertuzumab improved overall survival (OS) by 15.7 months to 56.5 months in treatment-naive patients, supporting the use of this triplet therapy in the clinic [108] . systemic management of HER2 + metastatic BC. Unfortunately, trastuzumab is less effective in controlling HER2 + CNS metastases [111] [112] [113] . Later it was found that the combination of lapatinib and capecitabine extended OS for HER2 + BCBM patients compared to trastuzumab alone [114, 115] . Further, Phase 2 results from the LAN-DSCAPE study indicated that combining lapatinib and capecitabine for first-line treatment of HER2 + BCBM showed activity by providing objective CNS responses in 65.9% of patients [116] . Most recently, adotrastuzumab emtansine (T-DM1), a trastuzumab molecule conjugated to a cytotoxic microtubule-destabilizing agent, was associated with longer OS when compared to the combination of lapatinib and capecitabine [117] . T-DM1 significantly improved OS vs. treatment of physician's choice in HER2 + metastatic breast cancer following two or more HER2-targeted treatment regimens in the phase 3 open-label TH3RESA trial [118] . To support the efficacy of T-DM1 in the treatment of HER2 + BCBM, a handful of small trials and case studies have reported promising results [119] [120] [121] [122] [123] . Perhaps the most encouraging results to date are those from the ongoing phase 3b KAMILLA study of T-DM1 in HER2 + BCBM patients which show that T-DM1 treatment decreases the size of brain target lesions in 84 of 126 patients with measurable CNS lesions [124] . Table 4 lists results of completed HER2 + BCBM clinical trials.
Novel chemotherapy for HER2 + brain metastases
The future of pharmacological intervention for the treatment of HER2 + BCBM looks bright, however many challenges remain. These include determining the precise BTB permeability of T-DM1 in HER2 + BCBM and to ascertain the mechanistic contributions of the trastuzumab molecule and DM1 molecule in conferring the cytotoxic actions of T-DM1 in the brain TME. The concurrent use of radiosurgery and T-DM1 elicited a 75% response rate in a small group of patients with HER2 + BCBM (n = 4): one complete response, one partial response, one stable disease, and one progression [125] . This report is supported by mechanistic data showing that T-DM1 provides potent and tumor selective radiosensitization [126] . The rational combination of T-DM1 with targeted therapies that inhibit over-activated pathways in HER2 + metastatic BC has also been an area of interest. A phase 1 study of T-DM1 in combination with alpelisib (BYL-719), an oral PI3K inhibitor, showed that the combination was safe and provided significant antitumor activity in metastatic BC patients previously treated with trastuzumab and taxane therapy [127] . It will be of great interest to determine whether combining T-DM1 with BBB-permeable targeted therapies that inhibit over-activated pathways in HER2 + BCBM confers greater benefit than T-DM1 alone. A phase 1b trial combining trastuzumab with PI3K inhibitor, buparlisib, showed an impressive disease control rate (75%) in HER2 + metastatic BC and supported the continuation to a phase 1b/2 trial including BM patients (NCT01132664) [128] . While this trial was ultimately terminated, many of the preclinical and clinical studies referenced above support a trial combining T-DM1 with a PI3K inhibitor (alpelisib or BBB-permeable buparlisib) for the treatment of HER2 + BCBM patients.
There are varieties of planned, recruiting, and active clinical trials for the treatment of HER2 + BCBM patients. The combination of everolimus, trastuzumab, and vinorelbine in treating this cohort is currently being investigated (NCT01305941). Others are seeking to determine whether T-DM1 in combination with metronomic temozolomide compared to T-DM1 alone confers secondary prevention of HER2 + BCBM following stereotactic radiosurgery (NCT03190967). An ongoing phase 2 study is looking at the efficacy of lapatinib for the treatment of HER2 + BCBM that have progressed following radiation treatment using whole brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) to the brain (NCT00263588). A planned phase 2 study by the Jules Bordet Institute will determine whether T-DM1 (Kadcyla) is effective in treating HER2 + BCBM (NCT03203616). To test whether HER2-targeted therapy resistance is a factor in the relative ineffectiveness of trastuzumab and pertuzumab for the treatment of HER2 + BCBM, a phase 1 trial will assess the combination in patients with new untreated asymptomatic or low symptomatic HER2 + BCBM (NCT02598427). A phase 1 study of T-DM1 in combination with sequential whole brain radiotherapy was competed, however no results have been posted yet (NCT02135159). Another phase 1 study is observing the effect of ARRY-380 (HER2-targeted agent that appears to have some brain penetration) in combination with trastuzumab for the treatment of HER2 + BCBM (NCT01921335). A phase 1 study combining lapatinib, WBRT, and trastuzumab reported a median PFS of 4.8 months and median OS of 18 months in HER2 + BCBM patients (NCT00470847).
The combination of neratinib (HKI-272) and capecitabine is currently being used in a phase 2 study at Dana-Farber Cancer Institute for the treatment of HER2 + BCBM (NCT01494662). The phase 1 LAPTEM trial combined lapatinib and temozolomide for the treatment of progressive Trastuzumab emtansine (T-DM1)
The Phase 3 EMILIA study found that HER2 + BCBM patients treated with T-DM1 (n = 45) had a median OS of 26.8 months compared to patients who received LC combination treatment (n = 50) having a median OS of 12.9 months. T-DM1 was shown to significantly decrease index lesion size (M1: from 1.6 cm to 0.8 cm) in one HER2 + BCBM patient. Of 10 HER2 + BCBM patients treated with T-DM1, 3 had partial remission, 2 had stable disease lasting for ≥ 6 months, 2 had stable disease for < 6 months, and 3 progressed. All 4 HER2 + BCBM patients treated with T-DM1 had 30% or greater reduction in tumor size, and 1 was maintained on therapy for 16 months. T-DM1 was administered to 39 HER2 + BCBM patients; median PFS was 6.1 months and one-year OS rate was 58%.
The Phase 3 TH3RESA trial found that HER2 + BCBM patients who received T-DM1 (n = 404) had a median OS of 22.7 months compared to patients who received treatment of physician's choice (TPC) (n = 198) having a median OS of 15.8 months.
Patients receiving HER2-targeted therapy have improvements in overall and progression-free survival. Despite poor intracranial penetration, trastuzumab alone or with emtansine have good outcomes compared to chemotherapy or placebo. OS: overall survival; PFS: progression-free survival. Table 5 Upcoming clinical trials for HER2 The success of lapatinib, capecitabine, trastuzumab and its conjugation to emtansine, have led these agents to be backbone therapy in the majority of newly initiated or in-progress trials for patients with HER2 + BCBM.
SR: stereotactic radiation; TPC: treatment of physician choice; WBRT: whole-brain radiation therapy. ness of cabozantinib ± trastuzumab (NCT02260531). Lastly, the combination of tucatinib, capecitabine, and trastuzumab will be compared to placebo, capecitabine, and trastuzumab in the phase 2 HER2CLIMB trial (NCT02614794). Table 5 outlines in-progress and upcoming HER2 + trials that include BM patients. Fig. 3 illustrates mechanism of HER2 + therapeutics.
Formulations involved in treating brain metastases
The BBB provides considerable resistance to chemotherapeutic agents. Specific physicochemical properties allow drugs access into the brain. General characteristics that promote BBB permeation have been summarized to have an optimal molecular weight 400-600 Da, higher lipophilicity and lower participation in hydrogen bonding. In an attempt to increase BBB permeability, chemical modification of drug molecules by charge reduction and addition of lipophilic moieties is a common approach. The BBB itself can be chemically targeted so that it transiently allows the passage of therapy across. Compounds such as bradykinin [129] and its synthetic analogues [130] , interleukin-2 [131] , and leukotriene C4 [132] have been used to open tight junctions as well as osmotic agents such as mannitol. However, this approach comes with the risk of adverse and of infections due to a compromised BBB. Adenosine receptor agonists using a dendrimer-based delivery have also been used to briefly open the BBB, reducing complications [133] .
Nanotechnology has become one of the defining standards in the development of "novel" therapeutic agents. Use of nanometer sized carriers for targeted delivery of chemotherapeutic drugs to brain metastases is one of the most commonly investigated approaches. Polymeric nanoparticles, solid-lipid nanoparticles, micelles, and liposomes are some of the delivery systems that can be used to achieve drug entry through the BBB. These novel drug delivery systems can be used to achieve spatial (site-specific) as well as temporal (time-dependent) control over treatment of brain metastases of breast cancer. Active targeting of the drugs can be achieved by delivering them via multifunctional nanoparticles. These systems have tumor specific moieties on their surface, which directs the carrier to the tumor site, where the drug is released. The main hypothesized advantage of using nanocarriers for cancer therapy is the Enhanced Permeation and Retention (EPR) effect. This concept was first laid down by Matsumura and Maeda, when they studied the tumor accumulation of a polymer conjugated protein neocarzinostatin, and a series of radiolabeled proteins of varying sizes [134] . Macromolecules tested were found to have a greater accumulation and longer retention in tumor tissue, as a function of their size. The observed phenomenon was attributed to twin effects [135] .
Tumor vasculature is leaky due to rapid angiogenesis and elevated levels of vascular permeability factors, facilitating the permeation of macromolecules into the tumor tissue. Additionally, the absence of proper lymphatic drainage supports longer retention of chemotherapy at the tumor site. This effect can be applicable to drug delivery systems such as nanoparticles, micelles, and liposomes [136] . The EPR effect is attributed to liposomal and nanoparticulate formulations showing tumor site accumulation. Unfortunately, adequate evidence does not exist for the EPR phenomenon. Only one clinical study showed accumulation of radiolabeled PEGylated liposomes in tumor tissues, an indication of the EPR effect [137] .
A mathematical model to quantify the EPR effect was developed based on pharmacokinetic data from the clinical trials of the FDA approved PEGylated liposomal formulation of doxorubicin, Doxil ® [138] .
This pharmacokinetic model considered the tumor as a separate compartment, and introduced rate constants for extravasation, as well as intravasation. The tumor accumulation of Doxil was significantly higher compared to that of conventional doxorubicin. It has been determined that drug delivery systems should preferably be biocompatible materials, a size of at least 40 kDa or more for the EPR effect to be applicable [139] , with the caveat that heterogeneity within the tumor tissue, and among tumor types, makes the EPR effect variable. Some of the parameters responsible for variable EPR effects include low systolic blood pressure, hypoxia, presence of emboli, and vascular density [140] . This phenomenon can be erratic with micellar and liposomal drug delivery systems, as they need to maintain system stability until they reach the site of action. The EPR effect has been used to predict therapeutic outcomes, but is not a reliable marker [140] . The therapeutic effect of the drug is a downstream effect that is dependent of other factors such as drug release and drug uptake. To make EPR more uniform, its augmentation has been described in rodents as well as humans using elevation of blood pressure [141] . Due to its heterogeneity, the EPR effect has been unsuccessful in a clinical setting, a stark contrast to its efficiency in pre-clinical murine models [142] . Better characterization of the EPR effect is required to create uniformity and reliability in clinical scenarios. Regardless of EPR in humans, nanoparticle based drug delivery systems still have relevance in terms of reducing the toxicity of chemotherapy drugs, localized delivery and imaging of tumor microenvironment [142] .
Drug delivery systems intended to target brain metastases
Liposomes
Liposomes are a drug delivery vehicle that consists of a phospholipid bilayer containing an inner, aqueous pocket. Hydrophilic drugs or imaging agents may be incorporated into the aqueous compartment, or hydrophobic ones in the lipid bilayer [143] . There are multiple types of liposome structures that may form when phospholipids are suspended in aqueous solution, including micelles and multilamellar or unilamellar vesicles. These liposomes may be generated via multiple methods; the most common being thin lipid film hydration. Freezethaw cycles, sonication, and extrusion through filters are additional procedures which may be used to control the vesicle type and size distribution [144] . Typically, liposomes used for clinical drug delivery are constructed from endogenous lipids such as cholesterol or their synthetic derivatives, have a size on the order of 100 nm diameter, and are unilamellar in structure [145, 146] .
The use of liposomes provides an opportunity for targeted drug delivery. Targeting ligands such as homing peptides and whole antibodies or their fragments, may be inserted on the surface of the liposomes [147] . This targeting confers liposomes the ability to potentially cross the BBB by adsorptive-mediated transcytosis (AMT) and receptormediated transcytosis [148] . AMT is a nonspecific mechanism in which the cationized surface of liposomes may interact with the anionic glycocalyx, stimulating their endocytosis and transport to the abluminal portion of the endothelial cell where they are exocytosed into the interstitial fluid of the CNS [149] . Receptor-mediated transcytosis works through a similar mechanism whereby receptors on the luminal surface of the endothelium, such as the insulin, transferrin, and LDL receptors, may bind to liposomes which have been labeled with ligands or antibodies for these receptors [147] [148] [149] [150] [151] [152] . These processes may result in three different fates for the liposome: they may pass through the endothelial cell completely and enter the brain, they may stay inside the endothelial cell, or they may be returned to the lumen of the vessel. These transcytotic pathways of BBB penetrance are the predominant pathways for liposomes because paracellular diffusion is limited by tight junctions and particle size [152] [153] [154] [155] [156] [157] [158] .
One common problem with nanoparticle vehicles, including liposomes, is their rapid clearance by the reticuloendothelial system. This problem is ameliorated in the case of liposomes by incorporating PEG into the lipid membrane [159] . While PEGylation provides more opportunities for attachment for targeting moieties and may reduce clearance, immunogenicity, and antigenicity, it can have negative effects, such as the increased accumulation in the skin, increasing the risk of developing hand-foot syndrome with some formulations. Non-PEGylated liposome formulations have also been developed, which overcome reticuloendothelial system clearance and immunogenicity [151] .
Preclinical data using a mouse model of brain metastases demonstrated a PEGylated liposomal formulation of irinotecan (MM-398) greatly enhanced its cytotoxic effect compared to conventional irinotecan [160] . Liposomal formulations of anthracyclines, such as Doxil ® , show improved efficacy and toxicity profiles in comparison to conventional formulations [161] . Several drug formulations including liposomes have already received FDA approval. These include liposomal preparations of cancer drugs such as doxorubicin (Doxil
, and vincristine (Marqibo ® ), which are being explored in the treatment of BCBM. Liposomal formulations developed for brain metastases have yet to be approved, but clinical trials using glutathione PEGylated liposomal doxorubicin (NCT01386580) and liposomal cytarabine (NCT00992602) are underway. Doxil ® is a marketed formulation of doxorubicin, delivered using PEGylated liposomes. The addition of PEG imparts a 'stealth' feature to the nanosystem, by allowing it to avoid premature clearance via the RES. A modified version of Doxil ® , was developed with an additional coating of glutathione [152] . Active transport of glutathione across the BBB helped enhance doxorubicin accumulation at the metastatic sites, as well as prolong circulation time. Doxorubicin bound to polysorbate 80-coated butyl cyanoacrylate nanoparticles was found to cross the intact BBB and reach therapeutic levels in the rat brain [162] . A multifunctional theranostic nanosystem was developed for the delivery of doxorubicin and diagnostic agents for brain metastases [163] . The system consisted of a terpolymer comprised of poly(methacrylic acid) and polysorbate 80 on a starch scaffold.
Conjugating nanoparticles
Housing therapeutics inside 10 nm-100 nm carriers allow for smaller doses to be given that simultaneously achieve similar or enhanced efficacy, a reduction in side-effect profile, prolonged dosing intervals, and enhanced accumulation compared to their conventional chemotherapy counterpart [164] . The carriers are often pegylated liposomes as described above, but conjugation to proteins such as transferrin or albumin are also used clinically. Paclitaxel has been formulated as polyethoxylated albumin bound nanoparticles (Abraxane ® ) and its published phase 2 [165] and phase 3 [166] clinical trials reported significant anti-tumor activity compared to standard paclitaxel. It targets the tumor by transcytosis, mediated by the albumin receptor (gp-60). The formulation, devoid of Cremophor EL solvent, was found to be safer. Microemulsion derived nanoparticles of paclitaxel have been prepared using cetyl alcohol and polysorbate as materials [167] . When tested in a rat model, the drug was shown to have an increased brain uptake and toxicity against P-gp expressing cancer cells, indicating a possible protection of paclitaxel from P-gp mediated efflux. Nanoparticles can also be used to house genetic therapy. A Phase 1 trial of nanoparticles housing the Rexin-G anti-cyclin G1 construct in the treatment of recurrent or metastatic breast cancer was started in July 2007, but no study results are posted as of 2011 (NCT00505271).
Conjugation of chemotherapy to other small molecules allows for targeting. Preclinical models of BCBM were found to have a prolonged survival when treated with nanoconjugates of paclitaxel and hyaluronic acid [168] . This formulation exploited passive diffusion across the BBB, and active tumor cell uptake due to the affinity of hyaluronic acid for CD44 receptors. The active targeting was aimed at circumventing the Pgp efflux that is observed with paclitaxel. Active targeting of mitoxantrone was achieved by targeting the LDL receptor related protein using angiopeptide-2 ligand conjugated on the surface of fluid membrane liposomes [153] . This formulation was found to have improved therapeutic potential in experimental brain metastasis model of breast cancer.
Pegylation
Polyethylene glycol (PEG) moiety attachment has been a frequent method employed by the pharmaceutical industry for nearly four decades to improve the systemic circulation of bioactive molecules with poor pharmacokinetic profiles [169] . PEGylation refers to the covalent adherence of multiple linear or branched polyethylene glycol molecules to a drug product [170] . PEGylation has been utilized in small molecules, liposomes, carbohydrates, enzymes, nucleotides and other nanotherapeutic strategies [171] [172] [173] . The most common molecule used during the PEGylating process is methoxy-polyethylene glycol (mPEG) [170] . Much like liposomes, the EPR effect can be exploited in the cancer setting. Large macromolecular therapies are able to passively enter tumors due to the presence of neo-angiogenesis and degree of permeability within tumor vasculature [135] .
PEG is known to enhance the pharmacokinetics of poorly circulating chemotherapeutics. In the case of the brain, PEG has been shown to increase the concentration of cytotoxic drugs reaching brain tissue [152] . PEG is also shown to enhance the bioavailability of orally available drugs by protecting them from catalytic degradation [174] .
While PEGylation also reduces the toxicity profile of many chemotherapeutic agents [175, 176] , this is not without its own drawbacks. After undergoing IV administration of PEGylated nanomedicines and small molecules, clotting and clumping can occur, initiating a cascade of detrimental side effects, such as embolism [177] . Hypersensitivity to PEGylated therapies is also an important concern. The complement activation cascade of the immune system is thought to play a role in immunogenicity of PEG molecule, which may lead to anaphylactic shock [178, 179] . Hypersensitivity can also be observed in the gastrointestinal tract and to dermatological preparations containing PEG [180] [181] [182] [183] [184] .
Another side effect to PEGylating compounds is the accelerated blood clearance (ABC) phenomenon. In the first mention of the ABC phenomenon, PEGylated liposomes were cleared at an accelerated rate during subsequent injection [185] . This observed effect further potentiates the idea of the immune system playing an important role in reaction to PEG molecules. The accelerated clearance may also indicate that size plays an important role, as previous experiments have shown that size is an important factor when considering ABC [186] . Perhaps, larger PEG molecules may elicit this effect to a greater degree. ABC is a poorly understood mechanism and warrants further research in regard to PEG.
PEG is an attractive therapeutic approach in cancer. Limiting systemic toxicity could provide many benefits to cytotoxic therapeutics. Oncaspar ® (pegaspargase), an L-asparaginase that is covalently conjugated to PEG and mPEG, is FDA-approved for the treatment of acute lymphoblastic leukemia [187] , though no clinical trials are planned for BCBM. Another PEGylated therapy being clinically investigated for BCBM is etirinotecan pegol (NKTR-102). This novel therapy is a fourarmed PEG polymer, with each arm ending with a hydrolysable ester linker and an irinotecan molecule [188] . In its preclinical studies, NKTR-102 was found to increase the duration of exposure and accumulation of SN-38 (the active metabolite of irinotecan) into tumors when compared to conventional irinotecan [188] . NKTR-102-treatment improved survival in a triple-negative brain metastatic model compared to conventional chemotherapy agents [189] . In the ATTAIN trial, BCBM patients are being recruited to test the efficacy of NKTR-102, with a primary outcome of CNS disease control rate (NCT02915744). Another PEGylated cancer therapeutic which has completed an open-label, PhaseI/2a clinical trial is glutathione PEGylated liposomal doxorubicin (2B3-101). 2B3-101 showed favorable improvements in overall survival in its preclinical studies over both PEGylated liposomal doxorubicin and vehicle [152] . 2B3-101 is thought to have increased targeting capabilities due to the presence of the glutathione acting as a targeting ligand [152] . The recently completed trial, for which no results have been reported as of yet, assessed the safety and tolerability of 2B3-101 in patients with brain metastases of solid tumors and malignant glioma over 16 months as well as its combination with trastuzumab in patients with HER2 + BCBM.
Physical devices
Several other therapeutic approaches hypothesized for treatment of primary brain tumors can be extrapolated to treat metastatic tumors as well. These include use of convection-enhanced therapy, Giladel ® (carmustine) wafers, osmotic BBB disruption, and ultrasound mediated BBB opening [190] . Ultrasound mediated disruption of BBB has been found to be effective in enhancing large molecule delivery, such as trastuzumab therapy [191] . This technique has been combined with using nanocarriers for drug delivery in brain metastases of breast cancer. Ultrasound induced hyperthermia has been employed to deliver doxorubicin encapsulated in a liposomal carrier for brain metastasis of breast cancer [192] . Significantly higher doxorubicin was measured in tumors with the combination as compared to treatment with doxorubicin liposomes alone.
Conclusion
The discovery of new biological targets has led to a resurgence and expansive interest in chemotherapy and dosage forms. New agents inhibiting PARP, CDK 4/6, PI3K, ILGF-1, estrogen pathways, HDAC, and HER2 + receptors and downstream effects, are being combined with traditional options such as radiation and surgery to develop new strategies to treat BCBM. Liposomes, conjugation to polymers, and nanoparticle sizing offer a route to repurpose conventional chemotherapy via the enhanced permeation and retention effect, which leads to reduced side effects, longer therapeutic windows, and less-frequent dosing intervals. With the combination of improved pharmacokinetic profiles and targeted chemotherapy, clinical trials are including patients with BCBM more frequently, and may provide substantial therapeutic advances to significantly extend overall survival for this diagnosis.
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